Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.

This $15M payment marks the second milestone achieved in the collaboration with Merck. Under the agreement, Neuphoria is eligible to receive up to $450M in additional milestone payments for certain ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to ...

Guggenheim maintained a Buy rating on Merck (NYSE:MRK) shares but reduced the price target to $115 from $122. The adjustment follows a comprehensive review of the pharmaceutical giant's fourth-quarter ...

Co's stock has reached a 52-week low, dipping to $85.71. This downturn reflects a significant shift from the previous year, with the pharmaceutical giant experiencing a 1-year change of -31.59%.

A key finding in January was the marked increase in procurement activity across North America. This increase was entirely ...

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...

Delta Corp Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 2,575.96 Crore) operating in Tourism & Hospitality sector. Delta Corp Ltd. key Products/Revenue Segments ...